Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

If Biotech manages to break out to new highs at some point this year, it would clear a significant resistance hurdle and open ...

Pharma trade bodies have warned of negative impacts from tariffs, while analysts point to geopolitical catalysts.

Here’s a roundup of the most significant insider buying and selling activity disclosed on Tuesday for U.S. publicly traded companies. Top buys. Lipocine Inc. (NASDAQ:LPCN) saw D ...

This biotech innovator in antibody therapies for IBD reported a notable insider sale amid ongoing preclinical development ...

Malawi breaking news publishing 24 hours a day news about Malawi, Malawi Business, Malawi Tourism, Malawi Politics, Malawi News ...

While there's been bad news, this company has more irons in the fire. The post Down 30% today, is it time to buy into this beaten-down biotech share? appeared first on The Motley Fool Australia.

Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from ...

Imagine your physician walks into the exam room, recommends a prescription medication, and casually mentions she’s being paid ...

The Trump administration will impose tariffs of as much as 100% on certain imported medicines, albeit with several major exemptions, a maneuver to pressure drugmakers to manufacture more in the US.

Uttar Pradesh State Industrial Development Authority and Jawaharlal Nehru Port Authority have partnered. This agreement aims ...

Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.